A Prospective, Multicenter Post-Market Clinical Follow-up Study to Evaluate the Safety and Performance of the Journey™ II UNI Unicompartmental Knee System

Smith & Nephew, Inc.6 sites in 3 countries154 target enrollmentAugust 10, 2018

ConditionsNon-inflammatory Degenerative Joint Disease (NIDJD) of the Knee

Overview

Phase: N/A
Intervention: Not specified
Conditions: Non-inflammatory Degenerative Joint Disease (NIDJD) of the Knee
Sponsor: Smith & Nephew, Inc.
Enrollment: 154
Locations: 6
Primary Endpoint: Implant survival 5 years postoperatively
Status: Completed
Last Updated: 9 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This clinical study will evaluate the early to midterm safety and performance of the JOURNEY™ II UNI UKS in patients with non-inflammatory degenerative joint disease of the knee requiring lateral or medial knee compartment replacement. Clinical, radiographic, health economic and safety outcomes will be evaluated.

Detailed Description

To assess the safety and performance of the JOURNEY™ II UNI UKS in patients with unicompartmental degeneration of the knee by demonstrating non-inferiority of the cumulative percent implant survival in subjects with the JOURNEY™ II UNI UKS implanted, compared to a literature reference rate of 91.7% (AOA annual report 2015)12 at 5 years.

Registry

clinicaltrials.gov

Start Date

August 10, 2018

End Date

May 19, 2025

Last Updated

9 months ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Smith & Nephew, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects must meet all of the following criteria for inclusion in the study.
•Unicompartmental, NIDJD, including OA, traumatic arthritis, or avascular necrosis.
•Eighteen (18) years of age or older at the time of surgery.
•Skeletally mature in the judgement of the PI.
•Has met an acceptable preoperative medical clearance and is free of (or acceptably managed) cardiac, pulmonary, hematological, infection, or other conditions that would pose an excessive operative risk.
•Willing and able to participate in required follow-up visits at the investigational site and to complete study procedures and questionnaires.
•Consented to participate in the study by signing the EC-approved ICF.

Exclusion Criteria

•Subjects meeting any of the following criteria must be excluded from participation in the study.
•Correction of functional deformity.
•Revision procedures where other treatments or devices have failed.
•Treatment of fractures that are unmanageable using other techniques.
•Inadequate bone stock to support the device which would make the procedure unjustifiable, including but not limited to severe osteopenia/osteoporosis or family history of severe osteoporosis/osteopenia.
•Body Mass Index (BMI) \>
•Collateral ligament insufficiency.
•Active infection, treated or untreated, systemic or at the site of the planned surgery or previous intra-articular infections.
•Incomplete or deficient soft tissue surrounding the knee.
•Conditions that may interfere with the UKA survival or outcome, including but not limited to Paget's disease, Charcot disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, renal insufficiency or neuromuscular disease.